U.S., April 19 -- ClinicalTrials.gov registry received information related to the study (NCT06934590) titled 'Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLC' on April 02.
Brief Summary: This is an open-label, dose-escalation Phase I study to evaluate the safety and tolerability of RX001 monotherapy in patients with advanced KRAS mutant NSCLC. Subjects aged >=19 years with advanced NSCLC with KRAS mutations will be enrolled. Based on the investigator's judgment of the lung tumor location, RX001 will be administered as a single intratumoral treatment via bronchoscopy or CT-guided percutaneous injection. Additionally, after conducting safety, tolerability, and preliminary anti-tumor efficacy assessments ...